|Bid||0.5659 x 900|
|Ask||0.5792 x 900|
|Day's Range||0.5735 - 0.5870|
|52 Week Range||0.4510 - 4.4400|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 23, 2022 - Aug 29, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.25|
Subscribe to Yahoo Finance Plus to view Fair Value for LCI
Lannett Company, Inc. (NYSE: LCI) today provided an update on its ongoing pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).
The recent price decline of 27% in Lannett Company, Inc.'s ( NYSE:LCI ) stock may have disappointed insiders who bought...
Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, USP, 50 mg/2mL, single dose vials.